July 17 (Reuters) - Abbott beat Wall Street

estimates for quarterly profit on Thursday, driven by strong

demand for its medical devices including continuous glucose

monitors.

Continuous glucose monitor makers such as Abbott, Dexcom ( DXCM )

and Medtronic ( MDT ) are riding a surge in demand as

diabetes awareness rises, insurance coverage expands, and

patients embrace finger-prick-free technology.

On an adjusted basis, the company reported a profit of $1.26

per share for the second quarter, compared with analysts'

average estimate of $1.25, according to data compiled by LSEG.

Abbott's quarterly revenue came in at $11.1 billion, in line

with expectations.

The medical device business, which sells diabetes and

heart-related devices among others, posted sales of $5.37

billion, topping estimates of $5.24 billion.

Abbott said on Thursday it planned to build a manufacturing

facility in the U.S state of Georgia by 2028 to support its

cardiovascular business.

This adds to April announcements for manufacturing and

research projects in Illinois and Texas, which are expected to

go live by the end of the year, and help Abbott mitigate any

likely impact from President Donald Trump's tariffs.

(Reporting by Puyaan Singh and Christy Santhosh in Bengaluru;

Editing by Sriraj Kalluvila)